Reported 2 days ago
Haemonetics Corporation (NYSE:HAE), despite reporting a 9% revenue decline in Q4 2025, received a stock upgrade from Hold to Buy by Citi, with a price target increase to $90. The company, based in Massachusetts and involved in medical technologies for blood and plasma collection, continues to demonstrate stability and a projected 11.12% EPS growth over the next five years, showcasing its potential for recovery and growth.
Source: YAHOO